Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $76,860 | $93,714 | $77,272 | $66,752 |
| - Cash | $2,488 | $2,730 | $3,106 | $2,886 |
| + Debt | $2,704 | $2,703 | $2,701 | $2,700 |
| Enterprise Value | $77,077 | $93,686 | $76,867 | $66,566 |
| Revenue | $14,202 | $13,117 | $12,173 | $16,072 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Gross Profit | $12,232 | $10,873 | $10,468 | $13,348 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| EBITDA | $5,318 | $4,693 | $5,260 | $9,669 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |
| Net Income | $4,413 | $3,954 | $4,338 | $8,075 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| % Growth | 10.3% | -9% | -46.9% | – |
| Operating Cash Flow | $4,421 | $4,594 | $5,015 | $7,081 |
| Capital Expenditures | -$756 | -$926 | -$590 | -$552 |
| Free Cash Flow | $3,665 | $3,668 | $4,425 | $6,529 |